(PTCT) PTC Therapeutics - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US69366J2006
Stock: Rare Disease Drugs, Gene Therapy, Central Nervous System
Total Rating 47
Risk 55
Buy Signal -0.48
| Risk 5d forecast | |
|---|---|
| Volatility | 59.0% |
| Relative Tail Risk | -25.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.57 |
| Alpha | -0.88 |
| Character TTM | |
|---|---|
| Beta | 1.236 |
| Beta Downside | 1.630 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.42% |
| CAGR/Max DD | 0.16 |
EPS (Earnings per Share)
Revenue
Description: PTCT PTC Therapeutics March 04, 2026
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company that develops and commercializes treatments for rare disorders.
The companys commercialized products include Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza for AADC deficiency, Tegsedi and Waylivra for other rare diseases, and Evrysdi for spinal muscular atrophy. The biopharmaceutical sector often focuses on orphan drugs due to premium pricing opportunities.
PTC Therapeutics also maintains a development pipeline, including Sepiapterin for phenylketonuria and PTC518 for Huntingtons disease, utilizing platform technologies. This business model frequently involves extensive R&D investment and collaborative partnerships.
Distribution occurs through third-party channels, and the company has multiple collaborations, including with F. Hoffman-La Roche Ltd. and Novartis Pharmaceuticals Corporation.
For more detailed financial and operational analysis, ValueRay offers in-depth company profiles.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 682.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.24 > 0.02 and ΔFCF/TA 34.68 > 1.0 |
| NWC/Revenue: 75.44% < 20% (prev 97.24%; Δ -21.81% < -1%) |
| CFO/TA 0.24 > 3% & CFO 711.2m > Net Income 682.6m |
| Net Debt (-492.4m) to EBITDA (887.7m): -0.55 < 3 |
| Current Ratio: 2.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (80.7m) vs 12m ago 4.52% < -2% |
| Gross Margin: 90.96% > 18% (prev 0.93%; Δ 9003 % > 0.5%) |
| Asset Turnover: 74.98% > 50% (prev 47.32%; Δ 27.66% > 0%) |
| Interest Coverage Ratio: 5.58 > 6 (EBITDA TTM 887.7m / Interest Expense TTM 152.2m) |
Altman Z'' 1.10
| A: 0.45 (Total Current Assets 2.27b - Total Current Liabilities 968.4m) / Total Assets 2.91b |
| B: -1.02 (Retained Earnings -2.96b / Total Assets 2.91b) |
| C: 0.37 (EBIT TTM 848.8m / Avg Total Assets 2.31b) |
| D: -0.95 (Book Value of Equity -2.95b / Total Liabilities 3.12b) |
| Altman-Z'' Score: 1.10 = BB |
Beneish M -2.39
| DSRI: 0.53 (Receivables 181.6m/158.6m, Revenue 1.73b/806.8m) |
| GMI: 1.02 (GM 90.96% / 92.89%) |
| AQI: 1.32 (AQ_t 0.17 / AQ_t-1 0.13) |
| SGI: 2.15 (Revenue 1.73b / 806.8m) |
| TATA: -0.01 (NI 682.6m - CFO 711.2m) / TA 2.91b) |
| Beneish M-Score: -2.39 (Cap -4..+1) = BBB |
What is the price of PTCT shares?
As of March 06, 2026, the stock is trading at USD 63.33 with a total of 1,074,202 shares traded.
Over the past week, the price has changed by -7.00%, over one month by -12.48%, over three months by -18.02% and over the past year by +21.95%.
Over the past week, the price has changed by -7.00%, over one month by -12.48%, over three months by -18.02% and over the past year by +21.95%.
Is PTCT a buy, sell or hold?
PTC Therapeutics has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy PTCT.
- StrongBuy: 7
- Buy: 3
- Hold: 5
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the PTCT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 87.6 | 38.3% |
| Analysts Target Price | 87.6 | 38.3% |
PTCT Fundamental Data Overview March 01, 2026
P/E Trailing = 7.9291
P/E Forward = 55.2486
P/S = 3.1635
P/B = 1743.2734
P/EG = 0.81
Revenue TTM = 1.73b USD
EBIT TTM = 848.8m USD
EBITDA TTM = 887.7m USD
Long Term Debt = 190.2m USD (estimated: total debt 492.3m - short term 302.1m)
Short Term Debt = 302.1m USD (from shortTermDebt, last quarter)
Debt = 492.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -492.4m USD (from netDebt column, last quarter)
Enterprise Value = 4.02b USD (5.47b + Debt 492.3m - CCE 1.95b)
Interest Coverage Ratio = 5.58 (Ebit TTM 848.8m / Interest Expense TTM 152.2m)
EV/FCF = 5.75x (Enterprise Value 4.02b / FCF TTM 698.9m)
FCF Yield = 17.38% (FCF TTM 698.9m / Enterprise Value 4.02b)
FCF Margin = 40.38% (FCF TTM 698.9m / Revenue TTM 1.73b)
Net Margin = 39.44% (Net Income TTM 682.6m / Revenue TTM 1.73b)
Gross Margin = 90.96% ((Revenue TTM 1.73b - Cost of Revenue TTM 156.5m) / Revenue TTM)
Gross Margin QoQ = 90.10% (prev 45.05%)
Tobins Q-Ratio = 1.38 (Enterprise Value 4.02b / Total Assets 2.91b)
Interest Expense / Debt = 11.21% (Interest Expense 55.2m / Debt 492.3m)
Taxrate = 2.01% (14.0m / 696.6m)
NOPAT = 831.8m (EBIT 848.8m * (1 - 2.01%))
Current Ratio = 2.35 (Total Current Assets 2.27b / Total Current Liabilities 968.4m)
Debt / Equity = -2.40 (negative equity) (Debt 492.3m / totalStockholderEquity, last quarter -205.3m)
Debt / EBITDA = -0.55 (Net Debt -492.4m / EBITDA 887.7m)
Debt / FCF = -0.70 (Net Debt -492.4m / FCF TTM 698.9m)
Total Stockholder Equity = -188.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 29.58% (Net Income 682.6m / Total Assets 2.91b)
RoE = -362.4% (negative equity) (Net Income TTM 682.6m / Total Stockholder Equity -188.3m)
RoCE = 46.6k% (out of range, set to none) (EBIT 848.8m / Capital Employed (Equity -188.3m + L.T.Debt 190.2m))
RoIC = 805.0% (NOPAT 831.8m / Invested Capital 103.3m)
WACC = 10.51% (E(5.47b)/V(5.97b) * Re(10.47%) + D(492.3m)/V(5.97b) * Rd(11.21%) * (1-Tc(0.02)))
Discount Rate = 10.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.37%
[DCF] Terminal Value 59.82% ; FCFF base≈698.9m ; Y1≈458.8m ; Y5≈209.3m
[DCF] Fair Price = 41.87 (EV 2.87b - Net Debt -492.4m = Equity 3.36b / Shares 80.3m; r=10.51% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 47.46 | EPS CAGR: -0.42% | SUE: -0.41 | # QB: 0
Revenue Correlation: 28.09 | Revenue CAGR: 2.75% | SUE: -0.41 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.46 | Chg7d=-0.060 | Chg30d=-0.060 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-12-31): EPS=-1.23 | Chg7d=-0.360 | Chg30d=-0.316 | Revisions Net=-1 | Growth EPS=-116.1% | Growth Revenue=-43.0%
EPS next Year (2027-12-31): EPS=3.10 | Chg7d=-0.105 | Chg30d=+0.795 | Revisions Net=-1 | Growth EPS=+351.6% | Growth Revenue=+21.5%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -2.1% (Discount Rate 10.5% - Earnings Yield 12.6%)
[Growth] Growth Spread = +23.4% (Analyst 21.3% - Implied -2.1%)
P/E Forward = 55.2486
P/S = 3.1635
P/B = 1743.2734
P/EG = 0.81
Revenue TTM = 1.73b USD
EBIT TTM = 848.8m USD
EBITDA TTM = 887.7m USD
Long Term Debt = 190.2m USD (estimated: total debt 492.3m - short term 302.1m)
Short Term Debt = 302.1m USD (from shortTermDebt, last quarter)
Debt = 492.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -492.4m USD (from netDebt column, last quarter)
Enterprise Value = 4.02b USD (5.47b + Debt 492.3m - CCE 1.95b)
Interest Coverage Ratio = 5.58 (Ebit TTM 848.8m / Interest Expense TTM 152.2m)
EV/FCF = 5.75x (Enterprise Value 4.02b / FCF TTM 698.9m)
FCF Yield = 17.38% (FCF TTM 698.9m / Enterprise Value 4.02b)
FCF Margin = 40.38% (FCF TTM 698.9m / Revenue TTM 1.73b)
Net Margin = 39.44% (Net Income TTM 682.6m / Revenue TTM 1.73b)
Gross Margin = 90.96% ((Revenue TTM 1.73b - Cost of Revenue TTM 156.5m) / Revenue TTM)
Gross Margin QoQ = 90.10% (prev 45.05%)
Tobins Q-Ratio = 1.38 (Enterprise Value 4.02b / Total Assets 2.91b)
Interest Expense / Debt = 11.21% (Interest Expense 55.2m / Debt 492.3m)
Taxrate = 2.01% (14.0m / 696.6m)
NOPAT = 831.8m (EBIT 848.8m * (1 - 2.01%))
Current Ratio = 2.35 (Total Current Assets 2.27b / Total Current Liabilities 968.4m)
Debt / Equity = -2.40 (negative equity) (Debt 492.3m / totalStockholderEquity, last quarter -205.3m)
Debt / EBITDA = -0.55 (Net Debt -492.4m / EBITDA 887.7m)
Debt / FCF = -0.70 (Net Debt -492.4m / FCF TTM 698.9m)
Total Stockholder Equity = -188.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 29.58% (Net Income 682.6m / Total Assets 2.91b)
RoE = -362.4% (negative equity) (Net Income TTM 682.6m / Total Stockholder Equity -188.3m)
RoCE = 46.6k% (out of range, set to none) (EBIT 848.8m / Capital Employed (Equity -188.3m + L.T.Debt 190.2m))
RoIC = 805.0% (NOPAT 831.8m / Invested Capital 103.3m)
WACC = 10.51% (E(5.47b)/V(5.97b) * Re(10.47%) + D(492.3m)/V(5.97b) * Rd(11.21%) * (1-Tc(0.02)))
Discount Rate = 10.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.37%
[DCF] Terminal Value 59.82% ; FCFF base≈698.9m ; Y1≈458.8m ; Y5≈209.3m
[DCF] Fair Price = 41.87 (EV 2.87b - Net Debt -492.4m = Equity 3.36b / Shares 80.3m; r=10.51% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 47.46 | EPS CAGR: -0.42% | SUE: -0.41 | # QB: 0
Revenue Correlation: 28.09 | Revenue CAGR: 2.75% | SUE: -0.41 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.46 | Chg7d=-0.060 | Chg30d=-0.060 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-12-31): EPS=-1.23 | Chg7d=-0.360 | Chg30d=-0.316 | Revisions Net=-1 | Growth EPS=-116.1% | Growth Revenue=-43.0%
EPS next Year (2027-12-31): EPS=3.10 | Chg7d=-0.105 | Chg30d=+0.795 | Revisions Net=-1 | Growth EPS=+351.6% | Growth Revenue=+21.5%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -2.1% (Discount Rate 10.5% - Earnings Yield 12.6%)
[Growth] Growth Spread = +23.4% (Analyst 21.3% - Implied -2.1%)